Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions

Chinese Medical Journal

Volumn 122, Issue 15, 2009, Pages 1732-1737

  Liu, Tao ^a,b   Xie, Ying ^a   Zhou, Yu Jie ^a   Li, Yue Ping ^a   Ma, Han Ying ^a   Guo, Yong He ^a   Liu, Yu Yang ^a   Zhao, Ying Xin ^a   Shi, Dong Mei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Daxing District People's Hospital   (China)

Author keywords

Acute; Angioplasty; Coronary syndrome; Percutaneous coronary; Tirofiban; Transluminal

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; ENOXAPARIN; TIROFIBAN; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGING; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE INJURY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBOCYTOPENIA;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; TYROSINE;

EID: 70349558041     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.15.003     Document Type: Article

References (22)

1. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-251.
2. Ivandic BT, Kurz K, Keck F, Staritz P, Lehrke S, Katus HA, et al. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes. Thromb Haemost 2008; 100: 648-654.
3. Rasoul S, Ottervanger JP, de Boer MJ, Dambrink JH, Suryapranata H, Hoorntje JC, et al. Routine upstream versus selective down stream use of tirofiban in non-ST elevation myocardial infarction patients scheduled for early invasive therapy; a randomized comparison. J Thromb Thrombolysis 2007; 24: 241-246.
4. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007; 297: 591-602.
5. Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol 2007; 23: 963-970.
6. Smith SC Jr, Dove JT, Jacobs AK. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019-3041.
7. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary inteventions: the EVEREST trial. J Am Coll Cardiol 2006; 47: 522-528.
8. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004; 44: 14-19.
9. Wyss CA, Roffi M. Platelet Inhibition in Percutaneous Coronary Interventions. Herz 2005; 30: 189-196.
10. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-2538.
11. Razakjr OA, Tan HC, Yip WL, Lim YT. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention. J Interv Cardiol 2005; 18: 33-37.
12. Macdonald SP, Nagree Y. Rapid risk stratification in suspected acute coronary syndrome using serial multiple cardiac biomarkers: a pilot study. Emerg Med Australas 2008; 20: 403-409.
13. Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002; 40: 662-668.
14. Li XM, Huang CX, Wang TS, Zhuang SW, Zhou H, Tian B. Comparison of coronary plaque composition among patients with acute coronary syndrome and stable coronary artery disease. Chin Med J 2008; 121: 534-539.
15. Gravning J, Ueland T, Morkrid L, Endresen K, Aaberge L, Kjekshus J. Different prognostic importance of elevated troponin I after percutaneous coronary intervention in acute coronary syndrome and stable angina pectoris. Scand Cardiovasc J 2008; 42: 214-221.
16. Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N. Effects of glycoprotein IIb/IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographically successful percutaneous coronary angioplasty. Cardiology 2004; 102: 18-23.
17. De Servi S, Mariani M, Vandoni P, Dellavalle A, Politi A, Poletti F, et al. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome. J Cardiovasc Med (Hagerstown) 2006; 7: 159-165.
18. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 1997; 96: 1445-1453.
19. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.
20. Leoncini M, Toso A, Maioli M, Bellandi F, Badia T, Politi A, et al. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream Tirofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. Am Heart J 2005; 150: 401.
21. Bolognese L. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Curr Med Res Opin 2007; 23: 1217-1226.
22. Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 1187-1193.